Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Mannkind Corporation
ClinicalTrials.gov Identifier:
NCT01544881
First received: February 23, 2012
Last updated: January 24, 2013
Last verified: January 2013

February 23, 2012
January 24, 2013
March 2012
September 2012   (final data collection date for primary outcome measure)
  • PK measures for TI Inhalation Powder (20U) as measured by area under the concentration-time curve (AUC 0-360) - timepoints: 0, 3, 6, 9, 12, 15, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150, 180, 240, 300 and 360 minutes post-TI dosing [ Time Frame: Crossover 1 time within 3 - 10 days ] [ Designated as safety issue: No ]
  • PK measures for RAA (8U) as measured by area under the concentration-time curve (AUC 0-360) - timepoints 0, 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150, 180, 210, 240, 270, 300 and 360 minutes post-RAA dosing [ Time Frame: Crossover 1 time within 3 - 10 days ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01544881 on ClinicalTrials.gov Archive Site
  • Safety variables including adverse events (AEs), clinical laboratory tests, vital signs and physical examinations [ Time Frame: Crossover 1 time within 3 - 10 days ] [ Designated as safety issue: No ]
  • Area under serum glucose infusion rate (GIR AUC 0-360) for TI Inhalation Powder (20U) as measured by: GIR AUC 0-360 timepoints: 0, 3, 6, 9, 12, 15, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150, 180, 240, 300 and 360 minutes post-TI dosing [ Time Frame: Crossover 1 time within 3 - 10 days ] [ Designated as safety issue: No ]
  • Area under serum glucose infusion rate (GIR AUC 0-360) for RAA (8U) as measured by: GIR AUC 0-360 timepoints: 0, 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150, 180, 210, 240, 270, 300 and 360 minutes post-RAA dosing [ Time Frame: Crossover 1 time within 3 - 10 days ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes
A Phase 1, Single-center, Open-label, Randomized, Crossover Design Clinical Study in Subjects With Type 1 Diabetes Comparing Insulin Exposure & Response Following Inhalation of Technosphere Insulin Inhalation Powder Using the Gen2C Inhaler Vs Subcutaneous Rapid-Acting Analog

This is an Open-label, randomized study in Type 1 diabetics looking at exposure and response (PK/PD) of TI using GEN2C Inhaler versus rapid acting analog.

Subjects with Type 1 diabetes will be randomized to either one dose of TI inhaled using the Gen2C device, or one dose of subcutaneously injected Rapid Acting Analog (RAA) and crossed over.

Crossover Sequences:

Sequence #1: Period 1 - one 20 U cartridge of TI; Period 2 - 8 U of RAA

Sequence #2: Period 1 - 8 U RAA; Period 2 - one 20 U cartridge of TI

An euglycemic clamp procedure will be performed at each dosing visit. The purpose of this study is to characterize the pharmacokinetics (PK) of the one dose of TI Inhalation Powder using the Gen2C inhaler as compared to one dose of subcutaneous RAA.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
Type 1 Diabetes Mellitus
  • Drug: Technosphere Insulin Inhalation Powder
    Inhalation Powder using the Gen2C inhaler
    Other Name: TI
  • Drug: Rapid Acting Analog
    Subcutaneous Injection
    Other Name: RAA
  • Experimental: TI Inhalation Powder
    Technosphere Insulin Inhalation Powder using the Gen2C inhaler
    Intervention: Drug: Technosphere Insulin Inhalation Powder
  • Active Comparator: RAA
    Rapid Acting Analog
    Intervention: Drug: Rapid Acting Analog
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
17
January 2013
September 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Men and women aged 18 to 60 years
  • One of more daily sc insulin injections of any insulin type or insulin pump use
  • Body mass index (BMI) = 30 kg/m2
  • Pulmonary function tests (PFTs) conducted at Visit 1:

    • FEV1 ≥ 80% of the Third National Health and Nutrition Examination Survey (NHANES III) predicted
    • FVC ≥ 80% of the Third National Health and Nutrition Examination Survey (NHANES III) predicted
  • Diagnosis of type 1 diabetes for at least 12 months
  • Good venous access for blood draws
  • Written informed consent provided
  • No smoking in the previous 6 months (including cigarette, cigars, pipes) and negative urine cotinine testing (<100 ng/mL)
  • C-peptide < 0.3 ng/mL
  • Hemoglobin A1c (HbA1c) = 10.0%

Exclusion Criteria:

  • Total daily insulin requirement of = 1.4 U/kg body weight
  • Serum creatinine = 2.0 mg/dL in men and > 1.8 mg/dL in women
  • Blood donation of 500 mL within the previous 56 days
  • Current treatment with pramlintide acetate or exenatide
  • Unstable diabetes control and evidence of severe complications of diabetes (ie, autonomic neuropathy)
  • History of chronic obstructive pulmonary disease (COPD) or asthma, or any other clinically important pulmonary disease confirmed by pulmonary function testing or radiologic findings
  • Upper respiratory tract infection within 8 weeks before screening
  • History of coronary artery disease, peripheral vascular disease, or congestive heart failure
  • Allergy to study drug, food, or other study material (eg, peanuts, soy products)
  • Clinically significant active or chronic illness
  • History of drug or alcohol abuse
  • Positive urine drug screen
  • Clinically significant screening ECG, physical examination, laboratory test, or vital sign abnormality
  • Exposure to any other investigational drug or device within 30 days before treatment or within 90 days before treatment for drugs known to modify glucose metabolism (except metformin)
  • History of malignancy within the 5 years before screening (other than basal cell carcinoma)
  • History of human immunodeficiency virus (HIV) infection or hepatitis B or C
  • Women who are pregnant, lactating, or planning to become pregnant during the clinical study period
  • Women of childbearing potential (defined as premenopausal and not surgically sterilized or postmenopausal for fewer than 2 years) not practicing adequate birth control. Adequate birth control is defined as using oral, percutaneous, or transdermal contraceptives; condoms and diaphragms (double barrier) with a spermicide; or intrauterine devices. Postmenopausal for the purposes of this clinical study includes experiencing amenorrhea for 2 or more years or being surgically sterile
  • Inability, in the opinion of the PI or a designee, to adequately inhale TI Inhalation Powder
  • Any subject who, in the opinion of the PI or a designee, appears to not be qualified for this study
Both
18 Years to 60 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01544881
MKC-TI-177
No
Mannkind Corporation
Mannkind Corporation
Not Provided
Study Chair: Chief Medical Officer Mannkind Corporation
Mannkind Corporation
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP